Amgen Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript
Okay. Great. Good morning, everyone. Welcome to the first day of the BofA Healthcare Conference. My name is Geoff Meacham. I'm the senior biopharma analyst here, and I have Aspen Mori from my team as well. And we're thrilled to have Amgen speak at our conference virtually, of course. And we have a lot of folks in the Amgen team, so we have Arvind Sood, who's Head of Investor Relations. We have Murdo Gordon, EVP Global Commercial Operations; Peter Griffith, CFO; and Dave Reese, EVP of R&D.
So we'll ask each one of them a number of questions, but Arvind, do you want to take (technical difficulty) questions?
Sounds great, Geoff. Many thanks for inviting us to your conference. We really appreciate the opportunity. Let me just tee up some key topics. We have all the subject matter experts this morning, so we look forward to having a dialogue. [As you heard from] Geoff, we recently reported our first quarter results and Q1 was impacted
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
